Evidence map›Paper›PMID 33921259›Full record

ReviewVaccines2021

Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia.

Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Ferdousi Begum, Shaikh A Shahed Hossain, Sukumar Sarker, Ananta Shrestha, Md Sakirul Islam Khan, Osamu Yoshida, Yoichi Hiasa

Abstract readReview
In one paragraph

Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Overview of Complications in Cirrhosis.Journal of clinical and experimental hepatology
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sheikh Mohammad Fazle AkbarDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Ehime 791-0295, Japan.
Mamun Al MahtabDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka 1000, Bangladesh.
Ferdousi BegumHoly Family Red Crescent Medical College, Dhaka 1000, Bangladesh.
Shaikh A Shahed HossainBRAC James P. Grant School of Public Health BRAC University, Dhaka 1212, Bangladesh.
Sukumar SarkerSave the Children Fund, Dhaka 1212, Bangladesh.
Ananta ShresthaLiver Foundation Nepal, Kathmandu 44600, Nepal.
Md Sakirul Islam KhanDepartment of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon City, Ehime 791-0295, Japan.ORCID 0000-0001-5734-0899
Osamu YoshidaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Ehime 791-0295, Japan.
Yoichi HiasaDepartment of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Ehime 791-0295, Japan.ORCID 0000-0003-4117-339X

Funding

Japan Agency for Medical Research and Development (AMED) 20fk0310103h1904
6 · The paper itself

Abstract

The World Health Organization (WHO) South-East Asia Regional Office (SEARO) covers 11 countries with a combined population of about 2 billion people, making it the most populous of the six WHO regions. In 1992, the WHO advocated including the hepatitis B vaccine in the Expanded Program of Immunization (EPI) and vaccinating all infants and children three times within 1 year of birth (HepB3). Recently, the WHO advocate birth-dose hepatitis B vaccination (HepB-BD) as soon as possible after birth, preferably within 24 hours. In 2016, the SEARO endorsed a regional hepatitis B control goal with a target of hepatitis B surface antigen (HBsAg) seroprevalence of ≤1% among children aged ≥5 years by 2020. Of the 11 SEARO countries, four achieved this target on schedule. Out of these four countries, two countries (Bangladesh and Nepal) have not adopted HepB-BD in EPI program. On the other hand, the coverage of HepB3 is not satisfactory in some SEARO countries, including India which adopted HepB-BD but could not achieve the overall target of SEARO. Thus, it is a point of debate whether emphasis should be placed on proper implementation of HepB3 or whether a new agenda of HepB-BD should be incorporated in developing countries of SEARO. The article discusses strengthening and expanding the Hepatitis B vaccination program in SEARO countries with an emphasis on HepB and HepB-BD programs.

Indexed as

birth-dose vaccineEPIhepatitis B vaccineSEARO

Identifiers

PMID33921259
PMCPMC8069988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.